ReviewTranslational cancer research2025
Current advances in the functional role of long non-coding RNAs in the oncogenesis and metastasis of esophageal squamous cell carcinoma: a narrative review.
Review in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A ferroptosis-related competing endogenous RNA network: HOX transcript antisense intergenic RNA/miR-129-5p/brain and acute leukemia, cytoplasmic axis contributes to the malignant progression of esophageal squamous cell carcinoma.Translational cancer research · 2026Article
- Transcriptome analysis and artificial intelligence for predicting lymph node metastasis of esophageal squamous cell carcinoma.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Esophageal squamous cell carcinoma (ESCC) is a significant global health challenge characterized by increasing incidence and generally poor prognosis. The search for novel biomarkers and therapeutic targets is crucial for improving patient outcomes. Long non-coding RNAs (lncRNAs) have emerged as key players in cancer research. The objective of this review is to explore the role of lncRNAs in ESCC, identifying their potential as diagnostic indicators and therapeutic targets. This review aims to provide a strategic overview of lncRNAs in ESCC, emphasizing their significance in disease progression and clinical implications for patient management. Methods: To identify published lncRNAs biomarkers for diagnosing or predicting the course of ESCC, we performed a literature search in the PubMed and PubMed Central databases, utilizing specific search terms. Key Content and Findings: This paper reviews the critical role of lncRNAs in ESCC and explores their functions in tumourigenesis and metastasis. Differential expression of lncRNAs is closely related to tumour aggressiveness and patient prognosis. Up-regulated lncRNAs usually promote tumour growth and predict poor prognosis, whereas down-regulated lncRNAs exert oncogenic effects and are associated with better clinical outcomes. In addition, lncRNAs play a role in the tumour microenvironment, influencing immune escape and treatment resistance. Despite the promising role of lncRNAs in ESCC therapy, their heterogeneity and complex regulatory mechanisms remain a challenge for clinical application. Future studies should focus on revealing their specific mechanisms and developing precise targeted therapeutic strategies to improve the outcome of ESCC patients. The dysregulation of lncRNAs correlates with tumor aggression and patient prognosis, underscoring a need for targeted therapies. Understanding lncRNAs mechanisms could pave the way for personalized medicine, enhancing early detection, and treatment efficacy in ESCC. Conclusions: LncRNAs represent a novel frontier in ESCC research, with significant implications for patient management. Future studies should focus on deciphering lncRNAs functions within ESCC's molecular landscape to facilitate the development of effective targeted therapies. The integration of lncRNAs research into clinical practice is poised to transform ESCC treatment strategies, offering hope for improved patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.